Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ann Mullally, M.D.


Effects of Mutant Calreticulin on Megakaryopoiesis in JAK2-unmutated Myeloproliferative Neoplasms
Summer, 05/27/14 - 08/29/14

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01HL131835 (MULLALLY, ANN) Aug 1, 2016 - May 31, 2021
    Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms
    Role: Principal Investigator
  2. K08HL109734 (MULLALLY, ANN) Aug 10, 2011 - Jul 31, 2016
    Functional and Molecular Dissection of Myeloproliferative Neoplasm Stem Cells
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, Heidel FH. Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature. 2020 12; 588(7836):157-163. PMID: 33239784.
  2. Kamaz B, Mullally A. COVID-19 and myeloproliferative neoplasms: some considerations. Leukemia. 2021 01; 35(1):279-281. PMID: 33106624.
  3. Ng J, Guo F, Marneth AE, Ghanta S, Kwon MY, Keegan J, Liu X, Wright KT, Kamaz B, Cahill LA, Mullally A, Perrella MA, Lederer JA. Augmenting emergency granulopoiesis with CpG conditioned mesenchymal stromal cells in murine neutropenic sepsis. Blood Adv. 2020 Oct 13; 4(19):4965-4979. PMID: 33049055.
    Citations:    Fields:    
  4. How J, Leiva O, Bogue T, Fell GG, Bustoros MW, Connell NT, Connors JM, Ghobrial IM, Kuter DJ, Mullally A, Neuberg D, Zwicker JI, Fogerty AE, Hobbs GS. Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res. 2020 Nov; 98:106459. PMID: 33022566.
    Citations:    Fields:    
  5. Jutzi JS, Mullally A. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN. Front Immunol. 2020; 11:2093. PMID: 32983162.
    Citations:    Fields:    
  6. Jacquelin S, Kramer F, Mullally A, Lane SW. Murine Models of Myelofibrosis. Cancers (Basel). 2020 Aug 23; 12(9). PMID: 32842500.
  7. Marneth AE, Mullally A. Busy signal: platelet-derived growth factor activation in myelofibrosis. Haematologica. 2020 Aug; 105(8):1988-1990. PMID: 32739885.
    Citations:    Fields:    
  8. Mullally A, Horgan T, Thompson M, Conlon C, Dempsey B, Higgins MF. Working in the shadows, under the spotlight - Reflections on lessons learnt in the Republic of Ireland after the first 18?months of more liberal Abortion Care. Contraception. 2020 Nov; 102(5):305-307. PMID: 32649949.
    Citations:    Fields:    
  9. Mullally A, Hood J, Harrison C, Mesa R. Fedratinib in myelofibrosis. Blood Adv. 2020 04 28; 4(8):1792-1800. PMID: 32343799.
    Citations: 1     Fields:    
  10. Marneth AE, Mullally A. The Molecular Genetics of Myeloproliferative Neoplasms. Cold Spring Harb Perspect Med. 2020 02 03; 10(2). PMID: 31548225.
    Citations: 5     Fields:    
  11. Mullally A. Both sides now: losses and gains of mutant CALR. Blood. 2020 01 09; 135(2):82-83. PMID: 31917838.
    Citations:    Fields:    Translation:HumansCells
  12. How J, Hobbs GS, Mullally A. Mutant calreticulin in myeloproliferative neoplasms. Blood. 2019 12 19; 134(25):2242-2248. PMID: 31562135.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  13. Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Gräsel J, Lansink L, Cooper L, Lee SJ, Chen NT, Lee CW, Haque A, Heidel FH, D'Andrea R, Hill GR, Mullally A, Milsom MD, Bywater M, Lane SW. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Leukemia. 2020 04; 34(4):1075-1089. PMID: 31732720.
    Citations: 2     Fields:    Translation:AnimalsCells
  14. Liu S, Marneth AE, Alexe G, Walker SR, Gandler HI, Ye DQ, Labella K, Mathur R, Toniolo PA, Tillgren M, Gokhale PC, Barbie D, Mullally A, Stegmaier K, Frank DA. The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. Blood Adv. 2018 12 11; 2(23):3428-3442. PMID: 30504235.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  15. Ciboddo M, Mullally A. JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):110-117. PMID: 30504299.
    Citations: 1     Fields:    Translation:Humans
  16. Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, Bindels EM, Heckl D, Büsche G, Fleck D, Müller-Newen G, Wongboonsin J, Ventura Ferreira M, Puelles VG, Saez-Rodriguez J, Ebert BL, Humphreys BD, Kramann R. Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell. 2018 Aug 02; 23(2):308-309. PMID: 30075132.
    Citations: 1     Fields:    
  17. Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, Silver AJ, Adams D, Castellano CA, Schneider RK, Padera RF, DeAngelo DJ, Wadleigh M, Steensma DP, Galinsky I, Stone RM, Genovese G, McCarroll SA, Iliadou B, Hultman C, Neuberg D, Mullally A, Wagner DD, Ebert BL. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018 04 11; 10(436). PMID: 29643232.
    Citations: 33     Fields:    Translation:AnimalsCells
  18. Abdelfattah NS, Mullally A. Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells. J Vis Exp. 2018 01 05; (131). PMID: 29364275.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  19. Elf S, Abdelfattah NS, Baral AJ, Beeson D, Rivera JF, Ko A, Florescu N, Birrane G, Chen E, Mullally A. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Blood. 2018 02 15; 131(7):782-786. PMID: 29288169.
    Citations: 16     Fields:    Translation:HumansCells
  20. Wong WJ, Hasserjian RP, Pinkus GS, Breyfogle LJ, Mullally A, Pozdnyakova O. JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. Haematologica. 2018 02; 103(2):e63-e68. PMID: 29146710.
    Citations: 4     Fields:    Translation:HumansCells
  21. Mullally A. Kinase Inhibitors in the Treatment of Myeloid Malignancies. Hematol Oncol Clin North Am. 2017 08; 31(4):ix-x. PMID: 28673398.
    Citations: 1     Fields:    Translation:HumansCells
  22. Hobbs GS, Rozelle S, Mullally A. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2017 08; 31(4):613-626. PMID: 28673391.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  23. Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, Bindels EM, Heckl D, Büsche G, Fleck D, Müller-Newen G, Wongboonsin J, Ventura Ferreira M, Puelles VG, Saez-Rodriguez J, Ebert BL, Humphreys BD, Kramann R. Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell. 2017 06 01; 20(6):785-800.e8. PMID: 28457748.
    Citations: 38     Fields:    Translation:HumansAnimalsCells
  24. Mead AJ, Mullally A. Myeloproliferative neoplasm stem cells. Blood. 2017 03 23; 129(12):1607-1616. PMID: 28159736.
    Citations: 17     Fields:    Translation:HumansCells
  25. Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D. Gain of function in Jak2V617F-positive T-cells. Leukemia. 2017 04; 31(4):1000-1003. PMID: 28074070.
    Citations:    Fields:    Translation:HumansAnimalsCells
  26. Mullally A. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms. Pathologe. 2016 Nov; 37(Suppl 2):175-179. PMID: 27796499.
    Citations:    Fields:    Translation:Humans
  27. Obeng EA, Chappell RJ, Seiler M, Chen MC, Campagna DR, Schmidt PJ, Schneider RK, Lord AM, Wang L, Gambe RG, McConkey ME, Ali AM, Raza A, Yu L, Buonamici S, Smith PG, Mullally A, Wu CJ, Fleming MD, Ebert BL. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016 09 12; 30(3):404-417. PMID: 27622333.
    Citations: 64     Fields:    Translation:HumansAnimalsCells
  28. Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally A. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov. 2016 Apr; 6(4):368-81. PMID: 26951227.
    Citations: 49     Fields:    Translation:HumansAnimalsCells
  29. Chen E, Ahn JS, Sykes DB, Breyfogle LJ, Godfrey AL, Nangalia J, Ko A, DeAngelo DJ, Green AR, Mullally A. RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Rep. 2015 Dec 22; 13(11):2345-2352. PMID: 26686625.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  30. Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015 Dec; 21(12):1473-80. PMID: 26569382.
    Citations: 29     Fields:    Translation:AnimalsCells
  31. Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, Arnason J, Berliner N. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016 Feb; 172(3):412-9. PMID: 26537747.
    Citations: 17     Fields:    Translation:Humans
  32. Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg D, Berliner N. Marked hyperferritinemia does not predict for HLH in the adult population. Blood. 2015 Mar 05; 125(10):1548-52. PMID: 25573993.
    Citations: 36     Fields:    Translation:Humans
  33. Ishikawa Y, Maeda M, Pasham M, Aguet F, Tacheva-Grigorova SK, Masuda T, Yi H, Lee SU, Xu J, Teruya-Feldstein J, Ericsson M, Mullally A, Heuser J, Kirchhausen T, Maeda T. Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology. Haematologica. 2015 Apr; 100(4):439-51. PMID: 25552701.
    Citations: 10     Fields:    Translation:AnimalsCells
  34. Bender M, Giannini S, Grozovsky R, Jönsson T, Christensen H, Pluthero FG, Ko A, Mullally A, Kahr WH, Hoffmeister KM, Falet H. Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood. 2015 Feb 05; 125(6):1014-24. PMID: 25468568.
    Citations: 13     Fields:    Translation:AnimalsCells
  35. Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):268-76. PMID: 25696866.
    Citations: 10     Fields:    Translation:HumansCells
  36. Lane SW, Mullally A. Hit the spleen, JAK! Blood. 2014 Nov 06; 124(19):2898-900. PMID: 25377558.
    Citations:    Fields:    Translation:HumansCells
  37. Chen E, Ahn JS, Massie CE, Clynes D, Godfrey AL, Li J, Park HJ, Nangalia J, Silber Y, Mullally A, Gibbons RJ, Green AR. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. Proc Natl Acad Sci U S A. 2014 Oct 21; 111(42):15190-5. PMID: 25288776.
    Citations: 13     Fields:    Translation:HumansCells
  38. Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, Ko A, Brumme K, Levine R, Ebert BL, Mullally A. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2015 Jan 08; 125(2):327-35. PMID: 25281607.
    Citations: 30     Fields:    Translation:AnimalsCells
  39. Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014 Oct 13; 26(4):509-20. PMID: 25242043.
    Citations: 47     Fields:    Translation:HumansAnimalsCells
  40. De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS One. 2014; 9(5):e96209. PMID: 24788138.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  41. Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014 Apr 07; 211(4):605-12. PMID: 24616378.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  42. Mullally A, Ebert BL. Sinister symbiosis: pathological hematopoietic-stromal interactions in CML. Cell Stem Cell. 2013 Sep 05; 13(3):257-8. PMID: 24012363.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  43. Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-a in a murine model of polycythemia vera. Blood. 2013 May 02; 121(18):3692-702. PMID: 23487027.
    Citations: 47     Fields:    Translation:HumansAnimalsCells
  44. Mullally A, Ebert BL. Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma. J Clin Oncol. 2012 Nov 20; 30(33):4168-70. PMID: 22965959.
    Citations: 5     Fields:    Translation:Humans
  45. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Sep 06; 489(7414):155-9. PMID: 22820254.
    Citations: 105     Fields:    Translation:HumansAnimalsCells
  46. Mullally A, Lane SW, Brumme K, Ebert BL. Myeloproliferative neoplasm animal models. Hematol Oncol Clin North Am. 2012 Oct; 26(5):1065-81. PMID: 23009938.
    Citations: 10     Fields:    Translation:HumansAnimals
  47. Lin X, Rice KL, Buzzai M, Hexner E, Costa FF, Kilpivaara O, Mullally A, Soares MB, Ebert BL, Levine R, Licht JD. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia. 2013 Feb; 27(2):344-52. PMID: 22864358.
    Citations: 28     Fields:    Translation:HumansCells
  48. Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood. 2012 Jul 05; 120(1):166-72. PMID: 22627765.
    Citations: 24     Fields:    Translation:AnimalsCells
  49. Wernig G, Kharas MG, Mullally A, Leeman DS, Okabe R, George T, Clary DO, Gilliland DG. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012 Apr; 26(4):720-7. PMID: 22005786.
    Citations: 7     Fields:    Translation:HumansAnimals
  50. Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood. 2011 Oct 27; 118(17):4666-73. PMID: 21873545.
    Citations: 30     Fields:    Translation:HumansAnimalsCells
  51. Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian JJ, Levine RL, Licht JD, Mullally A, Odenike O, Pardanani A, Silver RT, Solary E, Mughal T. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J. 2011 Mar 04; 1:e7. PMID: 23471017.
    Citations: 3     Fields:    
  52. Mullally A, Ebert BL. STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation. Cancer Cell. 2010 Nov 16; 18(5):405-6. PMID: 21075304.
    Citations:    Fields:    
  53. Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011 Mar 03; 117(9):2567-76. PMID: 21068437.
    Citations: 138     Fields:    Translation:HumansAnimalsCells
  54. Mullally A, Ebert BL. NF1 inactivation revs up Ras in adult acute myelogenous leukemia. Clin Cancer Res. 2010 Aug 15; 16(16):4074-6. PMID: 20587590.
    Citations: 5     Fields:    Translation:HumansCells
  55. Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010 Jun 15; 17(6):584-96. PMID: 20541703.
    Citations: 140     Fields:    Translation:HumansAnimalsCells
  56. Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A. CNS relapse in acute promyeloctyic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):e409-11. PMID: 20530270.
    Citations: 3     Fields:    Translation:HumansCells
  57. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 02; 114(1):144-7. PMID: 19420352.
    Citations: 255     Fields:    Translation:Humans
  58. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009 Apr; 41(4):455-9. PMID: 19287384.
    Citations: 113     Fields:    Translation:Humans
  59. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009 May; 23(5):900-4. PMID: 19262599.
    Citations: 72     Fields:    Translation:Humans
  60. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 May; 23(5):905-11. PMID: 19262601.
    Citations: 130     Fields:    Translation:Humans
  61. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood. 2007 Feb 15; 109(4):1355-62. PMID: 17008540.
    Citations: 32     Fields:    Translation:Humans
  62. Mullally AM, Vogelsang GB, Moliterno AR. Wasted sheep and premature infants: the role of trace metals in hematopoiesis. Blood Rev. 2004 Dec; 18(4):227-34. PMID: 15501551.
    Citations: 2     Fields:    Translation:HumansAnimals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mullally's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (292)
Co-Authors (62)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.